Cancer Res Treat.  2006 Jun;38(3):121-125.

A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer

• Park SH
• Jeon SY
• Ko KI
• Nam E
• Bang SM
• Cho EK
• Shin DB
• Lee JH
• Lee WK
• Chung M

Abstract

PURPOSE: Irinotecan, in combination with leucovorin/ 5-fluorouracil (FU) or with cisplatin, is known to be active for treating advanced gastric cancer (AGC). This pilot study evaluated a novel three-drug combination of irinotecan, leucovorin/FU and cisplatin as a first-line treatment of AGC. The primary endpoint was to assess the feasibility in anticipation of conducting a larger phase II study.
MATERIALS AND METHODS
Chemotherapy-naive AGC patients received irinotecan 150 mg/m2 on day 1, and leucovorin 200 mg/m2 and a 22-h infusion of FU 1000 mg/m2 on days 1 and 2. Cisplatin 30 mg/m2 was administered on day 2. Treatment was repeated every 2 weeks until disease progression or unacceptable toxicity.
RESULTS
Of the 17 eligible patients, two patients had an ECOG performance status of 2 and their median age was 48 years (range: 31 to 69). A total of 117 chemotherapy cycles were delivered (median: 6, range: 1 to 12). The causes of treatment discontinuation were disease progression in 9 patients (53%), refusal (35%) and toxicity (12%). Although grade 3 or 4 neutropenia (41% of patients) was the major toxicity that required dose adjustments, only one episode of febrile neutropenia occurred. Grade 3 or 4 nausea and vomiting, diarrhea and fatigue were observed in 35%, 35% and 29% of patients, respectively. None of the patients died of toxicity during treatment. Of the 16 patients who were evaluable for response, 7 (44%) experienced a partial response.
CONCLUSION
This novel multi-drug combination was tolerated well in patients with AGC. Based on the encouraging efficacy and tolerability, a randomized phase II study is ongoing in this disease setting.

Keyword

Stomach neoplasm; Irinotecan; 5-fluorouracil; Cisplatin

MeSH Terms

Cisplatin*
Diarrhea
Disease Progression
Disulfiram
Drug Therapy
Drug Therapy, Combination*
Fatigue
Febrile Neutropenia
Fluorouracil*
Humans
Leucovorin*
Nausea
Neutropenia
Pilot Projects*
Stomach Neoplasms*
Vomiting
Cisplatin
Disulfiram
Fluorouracil
Leucovorin

Figure

• 

  Fig. 1 Progression-free survival and overall survival.

Reference

1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat. 2002; 34:77–83.

2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–591. PMID: 7533517.

3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8:163–168. PMID: 9093725.

4. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. North Central Cancer Treatment Group. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol. 1994; 12:412–416. PMID: 8113849.

5. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol. 2003; 21:54–59. PMID: 12506170.

6. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006; 24:2188–2196. PMID: 16682738.

7. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15:261–267. PMID: 8996151.

8. Moiseyenko VM, Ajani JA, Tjulandin S, Van Cutsem E, Fodor M, Majlis A, et al. Final results of a randomized comtrolled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol. 2005; 23:308s. (abstr 4002).

9. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003; 89:997–1001. PMID: 12966415.

10. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004; 22:4319–4328. PMID: 15514373.

11. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002; 94:641–646. PMID: 11857295.

12. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004; 15:1773–1781. PMID: 15550582.

13. Schleucher N, Tewes M, Wilke HJ, Eberhardt W, Buechele T, Hense J, et al. Phase I/II study with weekly infusional high-dose 5-fluorouracil/leucovorin/irinotecan in combination with biweekly cisplatin as first-line chemotherapy for metastatic gastric carcinoma. Proc Am Soc Clin Oncol. 2003; 22:343. (abstr 1378).

14. In : Niederman TM, Stone E, editors. Fluorouracil, leucovorin, irinotecan, and cisplatin (FLIP) in chemotherapy naive metastatic gastric carcinoma: final results of a pilot phase II trial. 2006. Proc Gastrointestinal Cancers Symposium; abstr 79.

15. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38:143–151. PMID: 7082756.

16. Shin DB, Lee SI, Park SH, Bang SM, Cho EK, Lee JH. Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol. 2006; 24:abstr 14083.

17. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer. 1999; 35:371–379. PMID: 10448285.

18. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer. 2005; 92:1850–1854. PMID: 15870718.

19. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003; 21:3721–3728. PMID: 12963704.

20. Ychou M, Fabbro-Peray P, Perney P, Marcais O, Gouze C, Ribard D, et al. A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. Am J Clin Oncol. 1998; 21:233–236. PMID: 9626787.